The of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study

Journal of Surgical Oncology

Volumn 109, Issue 6, 2014, Pages 527-532

  Hompes, D ^a,b   D'Hoore, A ^a   Wolthuis, A ^a   Fieuws, S ^c   Mirck, B ^b   Bruin, S ^b   Verwaal, V ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c KU LEUVEN   (Belgium)

Author keywords

colorectal cancer; HIPEC; Mitomycin C; Oxaliplatin; peritoneal carcinomatosis

Indexed keywords

CREATININE; FLUOROURACIL; FOLINIC ACID; MITOMYCIN; OXALIPLATIN;

ABDOMINAL ABSCESS; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; COHORT ANALYSIS; COLORECTAL CANCER; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM FISTULA; FEMALE; HEMATOLOGIC DISEASE; HOSPITALIZATION; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; NEUTROPENIA; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SIDE EFFECT; URINARY DYSFUNCTION; URINARY TRACT FISTULA;

COLORECTAL CANCER; HIPEC; MITOMYCIN C; OXALIPLATIN; PERITONEAL CARCINOMATOSIS;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD LOSS, SURGICAL; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COHORT STUDIES; COLORECTAL NEOPLASMS; HUMANS; HYPERTHERMIA, INDUCED; LEUKOPENIA; LOGISTIC MODELS; MIDDLE AGED; MITOMYCIN; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; POSTOPERATIVE COMPLICATIONS; YOUNG ADULT;

EID: 84901824463     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23546     Document Type: Article

References (44)

1. Verwaal V, Bruin S, Boot H, et al.: 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-2432.
2. Franko J, Ibrahim Z, Gusani N, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 2010; 116: 3756-3762.
3. Elias D, Glehen O, Pocard M, et al.: A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel and nonpseudomyxoma appendix. Ann Surg 2010; 251: 896-901.
4. Elias D, Gilly F, Boutitie F, et al.: Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28: 63-68.
5. Verwaal V, van Ruth S, Witkamp A, et al.: Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12: 65-71.
6. Elias D, Lefevre J, Chevalier J, et al.: Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: 681-685.
7. Kusamura S, Elias D, Baratti D, et al.: Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2008; 98: 247-252.
8. van Ruth S, Mathôt R, Sparidans R, et al.: Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokinet 2004; 43: 131-143.
9. Soulié P, Raymond E, Brienza S, et al.: Oxaliplatin: The first DACH platinum in clinical practice. Bull Cancer 1997; 84: 665-673.
10. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
11. Makatsoris T, Kalafonos HP, Aravantinos G, et al.: A phase II study of capecitabine plus oxaliplatin (XELOX): A new first-line option in metastatic colorectal cancer. Int J Gastrointest Cancer 2005; 35: 103-109.
12. Scheithauer W, Kornek G, Raderer M, et al.: Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307-1312.
13. Alkis N, Demerci U, Benekli M, et al.: Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure. J BUON 2011; 16: 80-83.
14. Kang E, Choi Y, Kim J, et al.: Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. Asia Pac J Clin Oncol 2010; 6: 286-291.
15. Michalaki V, Gennatas S, Gennatas C, et al.: Mitomycin C and UFT/leucovorin as salvage treatment in patients with advanced colorectal cancer. J BUON 2010; 15: 270-273.
16. Vormittag L, Kornek G, Gruhsmann B, et al.: UFT/leucovorin and mitomicyn C as salvage treatment in patients with advanced colorectal cancer-A retrospective analysis. Anticancer Drugs 2007; 18: 709-712.
17. Elias D, Pocard M:, Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Oncol Clin N Am 2003; 12: 543-559.
18. van Leeuwen B, Graf W, Pahlman L, et al.: Swedish experience with peritonectomy and HIPEC in peritoneal carcinomatosis. Ann Surg Oncol 2008; 15: 745-753.
19. Gomes da Silva R, Sugarbaker P:, Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 2006; 203: 878-886.
20. Swellengrebel H, Zoetmulder F, Verwaal V, et al.: Quantitative intra-operative assessment of peritoneal carcinomatosis-A comparison of three prognostic tools. Eur J Surg Oncol 2009; 35: 1078-1084.
21. Jacquet P, Sugarbaker P:, Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In:, Sugarbaker PH, editor. Peritoneal carcinomatosis: Principles of management. Boston: Kluwer Academic Publishers; 1996. pp. 359-374.
22. Schemper M, Smith T:, A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
23. Pestieau S, Belliveau J, Griffin H, et al.: Pharmacokinetics of intraperitoneal oxaliplatin: Experimental studies. J Surg Oncol 2001; 76: 106-114.
24. Lambert L, Armstrong T, Lee J, et al.: Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 2009; 16: 2181-2187.
25. van Ruth S, Verwaal V, Zoetmulder F, et al.: Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am 2003; 12: 771-780.
26. Elias D, Bonnay J, Puizillou M, et al.: Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol 2002; 13: 267-272.
27. Elias D, Pocard M, Goere D, et al.: HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin. Cancer Treat Res 2007; 134: 303-318.
28. Mahteme H, Wallin I, Glimelius B, et al.: Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion. Eur J Clin Pharmacol 2008; 64: 907-911.
29. Bécouarn Y, Ychou M, Ducreux M, et al.: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients: Digestive Group of French Federations of Cancer Centers. J Clin Oncol 1998; 16: 2739-2744.
30. Elias D, Benizri E, Di Pietrantonio D, et al.: Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 2007; 14: 509-514.
31. De Somer F, Ceelen W, Delanghe J, et al.: Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 2008; 28: 61-66.
32. Ceelen W, Peeters M, Houtmeyers P, et al.: Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol 2008; 15: 535-541.
33. Maggiori L, Elias D:, Curative treatment of colorectal peritoneal carcinomatosis: Currents status and future trends. Eur J Surg Oncol 2010; 36: 599-603.
34. Verwaal V, van Ruth S, de Bree E, et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743.
35. Verwaal V, van Tinteren H, van Ruth S, et al.: Predicting the survival of patients with peritoneal carcinomatosis of colorectal origing treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004; 91: 739-746.
36. Verwaal V, van Tinteren H, van Ruth S, et al.: Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85: 61-67.
37. Elias D, Goere D, Blot F, et al.: Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43°C after complete cytoreductive surgery: Mortality and morbidity in 106 consecutive patients. Ann Surg Oncol 2007; 14: 1818-1824.
38. Votanopoulos K, Chukwuemeka I, Shen P, et al.: A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res 2013; 179: e133-e139.
39. Graham M, Lockwood G, Greenslade D, et al.: Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 2000; 6: 1205-1218.
40. Kautio A, Haanpää M, Kautiainen H, et al.: Oxaliplatin Scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy. Anticancer Res 2011; 31: 3493-3496.
41. Grothey A:, Oxaliplatin-safety: Neurotoxicity. Semin Oncol 2003; 30: 5-13.
42. Stuart O, Stephens A, Welch L:, Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. Ann Surg Oncol 2002; 9: 186-191.
43. Schmid K, Boettcher M, Pelz J, et al.: Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with mitomycin C. Eur J Surg Oncol 2006; 32: 1222-1225.
44. Näslund Andréasson S, Anundi H, Thorén S, et al.: Is platinum present in blood and urine from treatment givers during hyoerthermic intraperitoneal chemotherapy ? J Oncol 2010; 2010: 649719.